



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/40, 31/44	A1	(11) International Publication Number: WO 99/65483 (43) International Publication Date: 23 December 1999 (23.12.99)
(21) International Application Number: PCT/SE99/00732 (22) International Filing Date: 3 May 1999 (03.05.99) (30) Priority Data: 969/MAS/98 5 May 1998 (05.05.98) IN 9802118-1 15 June 1998 (15.06.98) SE (71) Applicant (for all designated States except US): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): BALGANESH, Meenakshi [IN/IN]; Astra Biochemicals Pvt Ltd., P.O. Box 8013, Malleswaram, Bangalore 560 080 (IN). ETHIRAJ, Kantharaj [IN/IN]; Astra Biochemicals Pvt Ltd., P.O. Box 8013, Malleswaram, Bangalore 560 080 (IN). GANGULY, Babita [IN/IN]; Astra Biochemicals Pvt Ltd., P.O. Box 8013, Malleswaram, Bangalore 560 080 (IN). JANAKI-RAMAN, Ramachandran [US/IN]; Astra Biochemicals Pvt Ltd., P.O. Box 8013, Malleswaram, Bangalore 560 080 (IN). KAUR, Parvinder [IN/IN]; Astra Biochemicals Pvt Ltd., P.O. Box 8013, Malleswaram, Bangalore 560 080 (IN). KAJIPALA, Rangarao [IN/IN]; Astra Biochemicals Pvt Ltd., P.O. Box 8013, Malleswaram, Bangalore 560 080 (IN). NANDAN, Santosh [IN/IN]; Astra Biochemicals		
Pvt Ltd., P.O. Box 8013, Malleswaram, Bangalore 560 080 (IN). MURUGAPPAN, Ramanujulu Pandi [IN/IN]; Astra Biochemicals Pvt Ltd., P.O. Box 8013, Malleswaram, Bangalore 560 080 (IN). RAMACHANDRAN, Narayanan [IN/IN]; Astra Biochemicals Pvt Ltd., P.O. Box 8013, Malleswaram, Bangalore 560 080 (IN). VENKATARAMAN, Balasubramanian [IN/IN]; Astra Biochemicals Pvt Ltd., P.O. Box 8013, Malleswaram, Bangalore 560 080 (IN). (74) Agent: ASTRA AKTIEBOLAG; Intellectual Property, Patents, S-151 85 Södertälje (SE). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).		
Published With international search report.		
(54) Title: MYCOBACTERIAL INHIBITORS (I) (57) Abstract Use of a compound of general formula (I), wherein x is 0 or 1; R¹, R², R³ and R⁴ have the definitions given in the description, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for use in the treatment of a mycobacterial disease.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

MYCOBACTERIAL INHIBITORS

The present invention relates to compounds for use in the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as

5 *Mycobacterium tuberculosis*, *M. bovis*, *M. avium* and *M. marinum*.

Tuberculosis is still a major public health problem affecting nearly all parts of the world. Based on skin test reactivity it has been estimated that about one-third of the world's population, i.e., 1.7 billion people, are infected with *Mycobacterium tuberculosis*.

10 Despite the availability of effective chemotherapies, it is responsible for three million deaths and from eight to ten million new cases annually and thus remains the leading cause of death world-wide due to a single infectious agent: 26% of all preventable deaths, 7% of all deaths. According to the World Health Organisation, 450,000 deaths per year due to tuberculosis in developing countries occur in children under fifteen years of age, and the
15 disease mostly affects the younger, more productive adults.


There are five front-line drugs known to be highly effective against *M. tuberculosis* and five second-line drugs that can be used when resistance to one or more of the front-line drugs is detected. The preferred mode of treatment for tuberculosis is the short course
20 chemotherapy in which there are two phases. The first phase consists of a daily regimen for two months with isoniazid (300 mg), rifampicin (600 mg), pyrazinamide (3 g) and ethambutol (1.5 g). The second phase or the continuation phase consists of a daily regimen for the next four months with isoniazid and rifampicin. Although infection with drug-sensitive strains of *M. tuberculosis* can be effectively cured with the short course
25 chemotherapy, the cure rate is very poor in most countries due to poor compliance which is reflective of the long duration of therapy.

The situation is further complicated by the rapid emergence of multi-drug resistant tuberculosis (MDR-TB) strains. For example, in certain populations, the incidence of
30 resistance to isoniazid is as high as 26% and the resistance to rifampicin is about 15%.

Prior to 1984, about 10% of tubercle bacilli isolated from patients in the United States were resistant to at least one single mycobacterial drug. By 1984, this figure had risen to 52%, of which over half (32%) were resistant to more than one drug (MDR-TB). Ten percent of the recorded MDR-TB cases have occurred in previously healthy people whose mortality rate - 70 to 90% - has been nearly the same as that of immunosuppressed individuals with MDR-TB. The number of cases of MDR-TB has doubled since 1984 and in many of them the tubercle bacilli are resistant to both isoniazid and rifampicin. The median interval between diagnosis of MDR-TB and death is only four weeks and therefore MDR-TB demands a shorter response time between diagnosis and appropriate commencement of treatment. However, MDR-TB is difficult to treat as such since most patients do not respond very well to the second-line drugs and the cost of alternate treatment procedures, including hospitalisation and possibly surgery, increases the cost to as much as ten times the cost of traditional treatment.

Thus, there is an urgent medical need to identify new drugs with significant therapeutic activity against single- or multiple-drug resistant strains of *M. tuberculosis* and with pharmacokinetic properties that permit reduced dosing which will in turn encourage better compliance.

In accordance with the present invention, there is therefore provided the use of a compound of general formula



wherein x is 0 or 1;

R^1 represents a hydrogen atom, or a C_1 - C_{20} alkyl or myrtanyl group, or a phenyl or benzyl group optionally substituted in the aromatic ring by one or more substituents selected from

amino, nitro, hydroxyl, carboxyl, halogen, trifluoromethyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxycarbonyl, piperidyl, piperazinyl and morpholinyl, or a group (CH₂)_yCONH-R⁵ where y is an integer from 1 to 6 and R⁵ represents a phenyl group optionally substituted by one or more substituents selected from amino, nitro, hydroxyl, carboxyl, halogen, trifluoromethyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxycarbonyl, piperidyl, piperazinyl and morpholinyl; and

either

R² represents a hydrogen atom or a C₁-C₆ alkyl group, or R² together with R³ represents a carbon-carbon single bond provided that x is 0, or R² together with R⁴ represents a group

=CH₂,

R³ represents a hydrogen atom or is linked to R² as defined above, and

R⁴ represents a hydrogen atom or a C₁-C₆ alkyl group; or a C₁-C₁₀ alkylamino group optionally substituted by a di(C₁-C₆ alkyl)amino substituent group; or an anilino group optionally substituted in the aromatic ring by one or more substituents selected from

amino, nitro, hydroxyl, carboxyl, halogen, trifluoromethyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxycarbonyl, piperidyl, piperazinyl and morpholinyl; or a group -SCH₂CH₂OH, -SCH₂CH₂NH₂, -SCH₂CH₂(NH₂)CO₂H or -SCH₂CH₂NHCO-R⁶ where R⁶ represents a C₁-C₁₀ alkyl or C₃-C₆ cycloalkyl group, or a phenyl group optionally substituted by one or more substituents selected from amino, nitro, hydroxyl, carboxyl, halogen, trifluoromethyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxycarbonyl, piperidyl, piperazinyl and morpholinyl; or R⁴ is linked to R² as defined above;

or

R², R³ and R⁴ together represent a phenyl group;

with the provisos that:

- (i) R¹, R², R³ and R⁴ do not each simultaneously represent a hydrogen atom,
- (ii) when x is 0, R¹ represents a 4-fluorophenyl group and R⁴ represents a hydrogen atom, then R² and R³ do not together represent a carbon-carbon single bond, and
- (iii) when x is 0, R¹ represents a 4-fluorophenyl group and R² and R³ both represent a hydrogen atom, then R⁴ does not represent an anilino, 4-chloroanilino, 2,6-dichloroanilino, 3,4-dichloroanilino, 2,5-dichloroanilino, 3-chloro-4-fluoroanilino or 4-fluoroanilino group;

or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for use in the treatment of a mycobacterial disease, in particular tuberculosis.

In the context of the present specification, unless otherwise stated, an alkyl
5 (substituent) group or an alkyl moiety in an alkoxy or alkoxycarbonyl substituent group may be linear or branched.

Preferably R^1 in formula (I) represents a hydrogen atom, or a C_1 - C_{15} , more preferably C_1 - C_{10} , alkyl or myrtanyl group, or a phenyl or benzyl group optionally substituted in the
10 aromatic ring by one to four, particularly one or two, substituents selected from amino, nitro, hydroxyl, carboxyl, halogen (e.g. fluorine, chlorine or bromine), trifluoromethyl, C_1 - C_4 alkyl (e.g. methyl, ethyl, propyl, isopropyl or butyl), C_1 - C_4 alkoxy (e.g. methoxy, ethoxy, propoxy, or butoxy), C_1 - C_4 alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl or butoxycarbonyl), piperidyl, piperazinyl and
15 morpholinyl, or a group $(CH_2)_yCONH-R^5$ where y is an integer 1, 2, 3 or 4 and R^5 represents a phenyl group optionally substituted by one to four, particularly one or two, substituents selected from amino, nitro, hydroxyl, carboxyl, halogen (e.g. fluorine, chlorine or bromine), trifluoromethyl, C_1 - C_4 alkyl (e.g. methyl, ethyl, propyl, isopropyl or butyl), C_1 - C_4 alkoxy (e.g. methoxy, ethoxy, propoxy, or butoxy), C_1 - C_4 alkoxycarbonyl (e.g.
20 methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl or butoxycarbonyl), piperidyl, piperazinyl and morpholinyl.

The group R^1 especially represents a hydrogen atom, or a C_4 - C_{10} alkyl (e.g. butyl, pentyl, hexyl, heptyl, octyl, nonyl or decyl) or myrtanyl group, or a phenyl group
25 substituted by a piperidyl substituent group, or a group $(CH_2)_yCONH-R^5$ where y is 1 or 2 and R^5 represents a phenyl group substituted by a piperidyl substituent group.

Preferably R^2 represents a hydrogen atom or a C_1 - C_4 alkyl, particularly methyl, group, or R^2 together with R^3 represents a carbon-carbon single bond provided that x is 0, or R^2 together with R^4 represents a group $=CH_2$.

5 R^4 preferably represents a hydrogen atom or a C_1 - C_4 alkyl group (e.g. methyl, ethyl, propyl or butyl); or a C_2 - C_{10} alkylamino group optionally substituted by a di(C_1 - C_6 alkyl)amino, especially di(C_1 - C_4 alkyl)amino, substituent group; or an anilino group optionally substituted in the aromatic ring by one to four, particularly one or two, substituents selected from amino, nitro, hydroxyl, carboxyl, halogen (e.g. fluorine, chlorine
10 or bromine), trifluoromethyl, C_1 - C_4 alkyl (e.g. methyl, ethyl, propyl, isopropyl or butyl), C_1 - C_4 alkoxy (e.g. methoxy, ethoxy, propoxy, or butoxy), C_1 - C_4 alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl or butoxycarbonyl), piperidyl, piperazinyl and morpholinyl; or a group $-SCH_2CH_2OH$, $-SCH_2CH_2NH_2$, $-SCH_2CH_2(NH_2)CO_2H$ or $-SCH_2CH_2NHCO-R^6$ where R^6 represents a C_5 - C_{10} alkyl or
15 C_3 - C_6 cycloalkyl group, or a phenyl group optionally substituted by one or more substituents selected from amino, nitro, hydroxyl, carboxyl, halogen (e.g. fluorine, chlorine or bromine), trifluoromethyl, C_1 - C_4 alkyl (e.g. methyl, ethyl, propyl, isopropyl or butyl), C_3 - C_6 alkoxy (e.g. propoxy, butoxy, pentoxy or hexyloxy), C_1 - C_4 alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl or butoxycarbonyl), piperidyl,
20 piperazinyl and morpholinyl; or R^4 is linked to R^2 as defined above.

It is preferred that R^4 represents a hydrogen atom, a methyl or ethyl group, a C_2 - C_{10} alkylamino group optionally substituted by a di(C_2 - C_4 alkyl)amino substituent group, an anilino group substituted by a piperidyl substituent group, $-SCH_2CH_2OH$, $-SCH_2CH_2NH_2$,
25 $-SCH_2CH_2(NH_2)CO_2H$, $-SCH_2CH_2NHCO-R^6$ where R^6 represents a C_7 alkyl, cyclopropyl, cyclopentyl or cyclohexyl group or a phenyl group substituted by a nitro, C_1 - C_4 alkyl or C_3 - C_6 alkoxy substituent group, or R^4 is linked to R^2 as defined above.

Particularly preferred compounds of formula (I) include:

30 1-Decylpyrrolidine-2,5-dione,

- 1-Nonylpiperidine-2,6-dione,
2-((6,6-Dimethylbicyclo[3,1,1]hept-2-yl)methyl)isoindole-1,3-dione,
1-((6,6-Dimethylbicyclo[3,1,1]hept-3-yl)methyl)-3-methyl-3-pyrroline-2,5-dione,
3-Methyl-1-nonyl-3-pyrroline-2,5-dione,
5 3-Methylene-1-nonylpyrrolidine-2,5-dione,
3-Methyl-1-octyl-3-pyrroline-2,5-dione,
3-Methylene-1-octylpyrrolidine-2,5-dione,
(4-(3-methyl-2,5-dioxo-3-pyrrolinyl)phenyl)piperidine,
1-Octyl-3-pyrroline-2,5-dione,
10 1-Decyl-3-pyrroline-2,5-dione,
1-Nonyl-3-pyrroline-2,5-dione,
1-Butyl-3-pyrroline-2,5-dione,
1-Hexyl-3-pyrroline-2,5-dione,
1-(4-Piperidylphenyl)-3-pyrroline-2,5-dione,
15 1-(Octyl-3-(octylamino)-pyrrolidine-2,5-dione,
1-Decyl-3-(decylamino)pyrrolidine-2,5-dione,
3-(Octylamino)-3-pyrrolidine-2,5-dione,
3-(Heptylamino)-1-nonyl pyrrolidine-2,5-dione,
1-Nonyl-3-(nonylamino) pyrrolidine-2,5-dione,
20 1-Nonyl-3-(octylamino) pyrrolidine-2,5-dione,
2-Amino-3-(3-methyl-1-nonyl-2,5-dioxo-pyrrolidin-3-ylthio)propanoic acid,
2-Amino-3-(3-methyl-1-octyl-2,5-dioxo-pyrrolidin-3-ylthio)propanoic acid,
2-Amino-3-(1-octyl-2,5-dioxo-pyrrolidin-3-ylthio)propanoic acid,
3-Methyl-1-octylpyrrolidine-2,5-dione,
25 3-Methyl-1-nonylpyrrolidine-2,5-dione,
2-(2,5-Dioxopyrrolidinyl)-N-(4-piperidylphenyl)ethanamide,
2-(2,5-Dioxopyrrolidinyl)-N-(4-piperidylphenyl)propanamide,
3-Ethyl-1-nonylpyrrolidine-2,5-dione,
3-(2-Aminoethylthio)-1-nonylpyrrolidine-2,5-dione,
30 2-Ethyl-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)hexanamide,

Cyclopropyl-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide,
 (4-Butylphenyl)-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide,
 (4-Hexyloxyphenyl)-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide,
 (4-Methylphenyl)-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide,
 5 (4-(tert-Butyl)phenyl)-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide,
 Cyclopentyl-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide, ethane,
 Cyclohexyl-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide,
 (4-Nitrophenyl)-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide,
 3-((2-(Dibutylamino)ethyl)amino)-1-nonylpyrrolidine-2,5-dione,
 10 3-((2-(Diethylamino)ethyl)amino)-1-nonylpyrrolidine-2,5-dione,
 1-Nonyl-3-((4-piperidinyphenyl)amino)pyrrolidine-2,5-dione,
 3-(Hydroxyethylthio)-3-methyl-1-nonylpyrrolidine-2,5-dione,
 3-(2-Aminoethylthio)-3-methyl-1-nonylpyrrolidine-2,5-dione, and
 3-Methyl-1-octyl-3-(octylamino)pyrrolidine-2,5-dione.

15

The compounds of formula (I) are known compounds or may be prepared using
 techniques conventional in the art. The compounds of formula (I) may, if desired, be
 converted to a pharmaceutically-acceptable salt or solvate thereof, preferably an acid
 addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate,
 20 tartrate, citrate, oxalate, methanesulphonate or *p*-toluenesulphonate, or an alkali metal salt
 such as a sodium or potassium salt.

Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It
 will be understood that the invention encompasses all geometric and optical isomers of the
 25 compounds of formula (I) and mixtures thereof including racemates. Tautomers and
 mixtures thereof also form an aspect of the present invention.

The compounds of formula (I) are advantageous in that they possess bactericidal
 activity against mycobacteria, particularly pathogenic mycobacteria such as *Mycobacterium*
 30 *tuberculosis*, *M. bovis*, *M. avium* and *M. marinum*.

Accordingly, in another aspect, the invention provides a method of treating a patient suffering from, or at risk of, a mycobacterial disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a
5 pharmaceutically-acceptable salt or solvate thereof, as defined above.

The compounds of formula (I) and pharmaceutically-acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active
10 ingredient) is in association with a pharmaceutically-acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.10 to 70 %w, of active ingredient, and, from 1 to 99.95 %w, more preferably from 30 to 99.90 %w, of a pharmaceutically-acceptable adjuvant, diluent or carrier, all percentages by weight being
15 based on total composition. The pharmaceutical composition may additionally contain another anti-tubercular agent and/or various other ingredients known in the art, for example, a lubricant, stabilising agent, buffering agent, emulsifying agent, viscosity-regulating agent, surfactant, preservative, flavouring or colorant.


20 The daily dosage of formula (I) compound administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the mycobacterial disease indicated. However, in general, satisfactory results will be obtained when the compound of formula (I) is administered at a daily dosage not exceeding 1 g, e.g. in the range from 10 to 50 mg/kg body weight.

25 The compounds of formula (I) may be administered systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions.

The present invention will now be further explained with reference to the following illustrative examples.

Example 1


5 1-Decylpyrrolidine-2,5-dione



Succinimide (0.1 M) dissolved in dry dimethylformamide was treated with sodium hydride
10 (0.1 M) at a temperature of 0° C. Nonyl bromide (0.1 M) was then added and the reaction mixture was stirred at room temperature for three hours. The reaction mixture was concentrated *in vacuo* and the residue extracted into ethyl acetate. The ethyl acetate layer was washed with water, dried over sodium sulphate and concentrated *in vacuo*. The residue obtained was chromatographed over silica gel to afford the desired product.
15 ¹HNMR: δ 0.75 (3H, t), 1.10-1.20 (12H, m), 1.35-1.45 (2H, m), 2.55 (4H, s), 3.35 (2H, dd)


Example 2

20 1-Nonylpiperidine-2,6-dione



The procedure of Example 1 was repeated except that glutarimide replaced the succinimide.

¹HNMR: δ 0.9 (3H, t), 1.2-1.3 (12H, m), 1.4-1.5 (2H, m), 1.9 (2H, p), 2.6 (4H, t),
25 3.7 (2H, dd)

Example 3**2-(((6,6-Dimethylbicyclo[3,1,1]hept-2-yl)methyl)isoindole-1,3-dione**

5


A solution of phthalic anhydride (0.1 M) in pyridine (20 ml) was treated with (-)-cis-myrtanylamine (0.1 M). The reaction mixture was heated to 90°C for six hours. The reaction mixture was then concentrated *in vacuo* and the residue was extracted into ethyl acetate. The ethyl acetate layer was washed with water and with cold aqueous hydrochloric acid, then dried over sodium sulphate and finally concentrated *in vacuo*. The residue

10

obtained was chromatographed over silica gel to afford the desired product.

¹HNMR: δ 0.85 (1H, d), 1.2 (6H, d), 1.5- 1.65 (2H, m), 1.80-2.05 (4H, m), 2.27-2.35 (1H, m), 2.45-2.60 (1H, m), 3.60-3.75 (2H, m), 7.65-7.70 (2H, m), 7.78-7.85 (2H, m)

15

Example 4**1-(((6,6-Dimethylbicyclo[3,1,1]hept-3-yl)methyl)-3-methyl-3-pyrroline-2,5-dione**

20

A solution of citraconic anhydride (0.1 M) in pyridine (20 ml) was treated with (-)-cis-myrtanylamine (0.1 M). The reaction mixture was heated to 90°C for six hours. The reaction mixture was then concentrated *in vacuo* and the residue was extracted into ethyl acetate. The ethyl acetate layer was washed with water and with cold aqueous hydrochloric acid, then dried over sodium sulphate and finally concentrated *in vacuo*. The residue


25

obtained was chromatographed over silica gel to afford the desired product.

^1H NMR: δ 0.65(1H, d), 1.0 (6H, d), 1.25-1.37 (1H, m), 1.55-1.80 (5H, m), 1.9 (3H, s), 2.08-2.25 (2H, m), 3.15-3.40 (2H, m), 6.1 (1H, s)

Example 5

5 3-Methyl-1-nonyl-3-pyrroline-2,5-dione




A solution of citraconic anhydride (0.1 M) in pyridine (20 ml) was treated with nonylamine (0.1 M). The reaction mixture was heated to 90°C for six hours. The reaction mixture was then concentrated *in vacuo* and the residue was extracted into ethyl acetate. The ethyl acetate layer was washed with water and with cold aqueous hydrochloric acid, then dried over sodium sulphate and finally concentrated *in vacuo*. The residue obtained was chromatographed over silica gel to afford the desired product.

15 ^1H NMR: δ 0.8 (3H, t), 1.15-1.30 (12H, m), 1.4-1.55 (2H, m), 2.05 (3H, s), 3.4 (2H, dd), 6.25 (1H, s)

Example 6

20 3-Methylene-1-nonylpyrrolidine-2,5-dione




A solution of itaconic anhydride (0.1 M) in pyridine (20 ml) was treated with nonylamine (0.1 M). The reaction mixture was heated to 90°C for six hours. The reaction mixture was then concentrated *in vacuo* and the residue was extracted into ethyl acetate. The ethyl

25

acetate layer was washed with water and with cold aqueous hydrochloric acid, then dried over sodium sulphate and finally concentrated *in vacuo*. The residue obtained was chromatographed over silica gel to afford the desired product.

5 **Example 7**

3-Methyl-1-octyl-3-pyrroline-2,5-dione




10 A solution of citraconic anhydride (0.1 M) in pyridine (20 ml) was treated with octylamine (0.1 M). The reaction mixture was heated to 90°C for six hours. The reaction mixture was then concentrated *in vacuo* and the residue was extracted into ethyl acetate. The ethyl acetate layer was washed with water and with cold aqueous hydrochloric acid, then dried over sodium sulphate and finally concentrated *in vacuo*. The residue obtained was
15 chromatographed over silica gel to afford the desired product.

¹HNMR: δ 0.85 (3H, t), 1.15-1.30 (12H, m), 1.45-1.60 (2H, m), 2.05 (2H, s), 3.45 (2H, dd), 6.27 (1H, s)

Example 8

20 **3-Methylene-1-octylpyrrolidine-2,5-dione**



A solution of itaconic anhydride (0.1 M) in pyridine (20 ml) was treated with octylamine
25 (0.1 M). The reaction mixture was heated to 90°C for six hours. The reaction mixture was


then concentrated *in vacuo* and the residue was extracted into ethyl acetate. The ethyl acetate layer was washed with water and with cold aqueous hydrochloric acid, then dried over sodium sulphate and finally concentrated *in vacuo*. The residue obtained was chromatographed over silica gel to afford the desired product.

5 ^1H NMR: δ 0.85 (3H, t), 1.20-1.35 (10H, m), 1.50-1.65 (2H, m), 3.3 (2H, s), 3.55 (2H, dd), 5.6 (1H, s), 6.35 (1H, s)

Example 9

(4-(3-methyl-2,5-dioxo-3-pyrrolinyl)phenyl)piperidine

10




A solution of citraconic anhydride (0.1 M) in pyridine (20 ml) was treated with 4-(1-piperidyl)aniline (0.1 M). The reaction mixture was heated to 90°C for six hours. The reaction mixture was then concentrated *in vacuo* and the residue was extracted into ethyl acetate. The ethyl acetate layer was washed with water and with cold aqueous hydrochloric acid, then dried over sodium sulphate and finally concentrated *in vacuo*. The residue obtained was chromatographed over silica gel to afford the desired product.

15 ^1H NMR: δ 1.5-1.75 (6H, m), 2.12 (3H, s), 3.18 (4H, t), 6.4 (1H, br s), 6.95 (2H, d), 7.1 (2H, d)

20

Example 10

1-Octyl-3-pyrroline-2,5-dione




To a solution of maleic anhydride (0.1 M) in acetone (150 ml), maintained at 0 °C, was added octylamine (0.1 M) dropwise over a 15 minute period. The reaction mixture was stirred for an additional period of one hour, and the white crystalline N-octyl maleimic acid
5 that separated was filtered and dried.

A mixture of N-octyl maleimic acid (0.1 M) and sodium acetate (0.1 M) in acetic anhydride (150 ml) was heated on a steam bath for two hours. The acetic anhydride was removed under vacuum and the residual liquid product was taken up in ethyl acetate,
10 washed with water, dried with sodium sulfate and concentrated to give a viscous liquid. Purification by flash chromatography (10% ethyl acetate in petroleum ether) yielded the desired product.

$^1\text{H NMR}$: δ 0.82 (3H, t), 1.15-1.4 (10H, m), 1.48-1.6 (2H, m), 3.45 (2H, dd), 6.65 (2H, s)


15 **Example 11**

1-Decyl-3-pyrroline-2,5-dione



20 The procedure of Example 10 was repeated using decylamine in place of octylamine.


$^1\text{H NMR}$: δ 0.85 (3H, t), 1.15-1.30 (14H, m), 1.50-1.60 (2H, m), 3.47 (2H, dd), 6.65 (2H, s)

Example 12**1-Nonyl-3-pyrroline-2,5-dione**

5

The procedure of Example 10 was repeated using nonylamine in place of octylamine.


$^1\text{HNMR}$: δ 0.85 (3H, t), 1.15-1.35 (12H, m), 1.5-1.6 (2H, m), 3.45 (2H, t), 6.65 (1H, s)

Example 1310 **1-Butyl-3-pyrroline-2,5-dione**

The procedure of Example 10 was repeated using butylamine in place of octylamine.

15

$^1\text{HNMR}$: δ 0.9 (3H, t), 1.25 (2H, m), 1.6 (2H, m), 3.5 (2H, dd), 6.65 (2H, s)

Example 14**1-Hexyl-3-pyrroline-2,5-dione**

20


The procedure of Example 10 was repeated using hexylamine in place of octylamine.

¹HNMR: δ 0.85 (3H, t), 1.2-1.35 (6H, m), 1.45-1.60 (2H, m), 3.45 (2H, dd), 6.65 (2H, s)

Example 15

1-(4-Piperidylphenyl)-3-pyrroline-2,5-dione

5




The procedure of Example 10 was repeated using 4-(piperidyl)aniline in place of octylamine.

10 ¹HNMR: δ 1.5-1.65 (6H, m), 3.0-3.12 (4H, m), 6.80 (2H, s), 6.95 (2H, d), 7.1 (2H, d)

Example 16

1-(Octyl-3-(octylamino)-pyrrolidine-2,5-dione


15



20

A mixture of N-octyl maleimide (0.01 M) prepared as described in Example 10 above, octylamine (0.01 M), triethylamine [catalytic, 0.1 equivalent] in acetonitrile (25 ml) was stirred for 24 hours at room temperature. Acetonitrile was removed under vacuum to leave a residual liquid product which was flash chromatographed (25% ethyl acetate in petroleum ether) to yield a white solid as the desired product.

¹HNMR: δ 0.8 (6H, t), 1.15-1.35 (20H, m), 1.45-1.65 (4H, m), 1.7 (1H, s), 2.45-2.65 (3H, m), 2.88 (1H, dd), 3.25 (2H, dd), 3.7 (1H, dd)

Example 17**1-Decyl-3-(decylamino)pyrrolidine-2,5-dione**

5


A mixture of N-decyl maleimide (0.01 M) prepared as described in Example 11 above, decylamine (0.01 M), triethylamine [catalytic, 0.1 equivalent] in acetonitrile (25 ml) was stirred for 24 hours at room temperature. Acetonitrile was removed under vacuum to leave a residual liquid product which was flash chromatographed (25% ethyl acetate in petroleum ether) to yield a white solid as the desired product.

10

¹HNMR: δ 0.8 (6H, t), 1.15-1.35 (24H, m), 1.45-1.65 (4H, m), 1.7 (1H, s), 2.45-2.65 (3H, m), 2.88 (1H, dd), 3.25 (2H, dd), 3.71 (1H, dd)

Example 18

15

3-(Octylamino)-3-pyrrolidine-2,5-dione


20

A mixture of maleimide (0.01 M), octylamine (0.01 M), triethylamine [catalytic, 0.1 equivalent] in acetonitrile (25 ml) was stirred for 24 hours at room temperature. Acetonitrile was removed under vacuum to leave a residual liquid product which was flash chromatographed (25% ethyl acetate in petroleum ether) to yield a white solid as the desired product.

¹HNMR: δ 0.85 (3H, t), 1.15-1.35 (10H, m), 1.42-1.55 (2H, m), 2.50-2.70 (3H, m), 2.90 (1H, dd), 2.80 (1H, dd)

Example 19


3-(Heptylamino)-1-nonylpyrrolidine-2,5-dione



A mixture of N-nonyl maleimide (0.01 M) prepared as described in Example 12 above, heptylamine (0.01 M), triethylamine [catalytic, 0.1 equivalent] in acetonitrile (25 ml) was stirred for 24 hours at room temperature. Acetonitrile was removed under vacuum to leave a residual liquid product which was flash chromatographed (25% ethyl acetate in petroleum ether) to yield a white solid as the desired product.

Example 20

1-Nonyl-3-(nonylamino)pyrrolidine-2,5-dione




A mixture of N-nonyl maleimide (0.01 M) prepared as described in Example 12 above, nonylamine (0.01 M), triethylamine [catalytic, 0.1 equivalent] in acetonitrile (25 ml) was stirred for 24 hours at room temperature. Acetonitrile was removed under vacuum to leave a residual liquid product which was flash chromatographed (25% ethyl acetate in petroleum ether) to yield a white solid as the desired product.

^1H NMR: δ 0.85 (6H, t), 1.15-1.38 (24H, m), 1.40-1.55 (4H, m), 1.70 (1H, br s), 2.45-2.70 (3H, m), 2.85 (1H, dd), 3.45 (2H, dd), 3.70 (1H, dd)

Example 21

5 1-Nonyl-3-(octylamino)pyrrolidine-2,5-dione




A mixture of N-nonyl maleimide (0.01 M) prepared as described in Example 12 above,
 10 octylamine (0.01 M), triethylamine [catalytic, 0.1 equivalent] in acetonitrile (25 ml) was stirred for 24 hours at room temperature. Acetonitrile was removed under vacuum to leave a residual liquid product which was flash chromatographed (25% ethyl acetate in petroleum ether) to yield a white solid as the desired product.

^1H NMR: δ 0.8-0.9 (6H, m), 1.18-1.30 (20H, m), 1.35-1.60 (4H, m), 2.5-2.6 (3H, m),
 15 2.7-3.0 (5H, m), 3.45 (2H, dd)

Example 22

2-Amino-3-(3-methyl-1-nonyl-2,5-dioxo-pyrrolidin-3-ylthio)propanoic acid



20


DL-Cysteine (0.0067 M) was dissolved in potassium acetate (50 mM) and the solution obtained was added slowly to N-nonyl itaconimide (0.004 M) prepared as described in Example 6 above. The reaction mixture was then dissolved in dimethylformamide with

gentle stirring and triethylamine was added. Stirring was continued for a further four hours at room temperature. The progress of the reaction was monitored by reverse phase thin layer chromatography using 75% methanol in water system. The formation of the desired product was detected by the ninhydrin reaction.

5

Example 23

2-Amino-3-(3-methyl-1-octyl-2,5-dioxo-pyrrolidin-3-ylthio)propanoic acid



10


The procedure according to Example 22 was repeated using the imide of Example 8 above.

^1H NMR: δ 0.85 (3H, t), 1.15-1.32 (10H, m), 1.3 (3H, d), 1.4-1.52 (2H, m), 2.65-2.85 (2H, m), 3.00-3.30 (2H, m), 3.42 (2H, t), 3.85 (1H, dd)

15


Example 24

2-Amino-3-(1-octyl-2,5-dioxo-pyrrolidin-3-ylthio)propanoic acid



20

The procedure according to Example 22 was repeated using the imide of Example 10 above.


Example 25**3-Methyl-1-octylpyrrolidine-2,5-dione**

5

10% Palladium on carbon catalyst (5 wt%) was added to a stirred solution of N-nonyl citraconimide (0.02 M) prepared as described in Example 5 above in methanol (100 ml). Hydrogen gas was bubbled through this solution for three hours. The solution was then filtered over celite and concentrated *in vacuo*. Chromatography over silica gel gave the

10 desired product.


¹HNMR: δ 0.85 (3H, t), 1.15-1.3 (10H, m), 1.3 (3H, d), 1.47-1.60 (2H, m), 2.28 (1H, dd), 2.77-2.95 (2H, m), 3.45 (2H, dd)

Example 2615 **3-Methyl-1-nonylpyrrolidine-2,5-dione**

The procedure of Example 25 was repeated using instead N-octyl citraconimide prepared as described in Example 7 above.

20 as described in Example 7 above.

¹HNMR: δ 0.85 (3H, t), 1.15-1.3 (12H, m), 1.3 (3H, d), 1.47-1.60 (2H, m), 2.28 (1H, dd), 2.77-2.95 (2H, m), 3.45 (2H, dd)

Example 27**2-(2,5-Dioxopyrrolidinyl)-N-(4-piperidylphenyl)ethanamide**

5

A solution of glycine benzyl ester hydrochloride (0.1 mM) in diethyl ether was treated with triethylamine (0.11 mM) and then with succinic anhydride (0.11 mM). The reaction mixture was stirred at room temperature for two hours and then partitioned between 10% aqueous hydrochloric acid and ethyl acetate. The ethyl acetate layer was separated, dried
10 over sodium sulphate and concentrated *in vacuo* to afford a yellow oil.

This oil was dissolved in acetic anhydride (20 ml) containing sodium acetate (0.1 mM) and heated to 90°C for three hours. The reaction mixture was cooled, poured into water and extracted thrice with ethyl acetate. The ethyl acetate layer was separated, dried over
15 sodium sulphate and concentrated *in vacuo* to afford a yellow oil. Chromatography over silica gel gave the succinoyl glycine benzyl ester.

10% Palladium on carbon catalyst (5 wt%) was added to a stirred solution of the succinoyl benzyl ester (0.009 M) in methanol (50 ml). Hydrogen gas was bubbled through this
20 solution for three hours. The solution was then filtered over celite and concentrated *in vacuo* to give the corresponding acid as a white solid.


A solution of the acid (0.1 mM) in dry dichloromethane was cooled to 0°C and treated with dimethylformamide (0.1 mM) followed by oxalyl chloride (0.1 mM). The cooling bath
25 was removed and the reaction mixture was refluxed for one hour. 4-(piperidyl)aniline (0.1 mM) was then added to the reaction mixture and this solution was stirred for two hours at room temperature. The reaction was then diluted with dichloromethane, washed

with saturated aqueous sodium bicarbonate and water. The organic layer was dried over sodium sulphate and concentrated *in vacuo*. The residue obtained was chromatographed to afford the desired product.

¹HNMR: δ 1.5-1.7 (6H, m), 2.8 (4H, s), 3.10 (4H, t), 4.3 (2H, s), 6.85 (2H, d),
5 7.30 (2H, d), 7.42 (1H, br s)

Example 28

2-(2,5-Dioxopyrrolidinyl)-N-(4-piperidylphenyl)propanamide




The procedure according to Example 27 was repeated using instead β-alanine benzyl ester hydrochloride.

¹HNMR: δ 1.50-1.85 (6H, m), 2.65-2.80 (6H, m), 3.05 (4H, t), 3.9 (2H, t), 6.85 (2H, d),
15 7.35 (2H, d), 7.4-7.5 (1H, br s)

Example 29

3-Ethyl-1-nonylpyrrolidine-2,5-dione



A solution of succinimide (15.15 mM) in tetrahydrofuran (15 ml) containing hexamethyl phosphorus triamide at -78 °C was treated with a solution of lithium diisopropylamide (30.30 mM) in tetrahydrofuran (25 ml). This solution was stirred at -78 °C for one hour
25 and then treated with ethyl iodide (15.90 mM). The reaction mixture was stirred at -78 °C

for 30 minutes, warmed up to room temperature and quenched with saturated aqueous ammonium chloride. The organic layer was separated and the aqueous layer extracted with ethyl acetate(3 x 25 ml). The combined organic layers were washed with 10% aqueous sodium thiosulfate, brine, dried over sodium sulfate and concentrated *in vacuo*.

5 Chromatography over silica gel afforded pure 3-ethyl succinimide.

A solution of 3-ethyl succinimide (4.72 mM) in dimethylformamide (10 ml) was treated with sodium hydride (5.20 mM) and nonyl bromide (5.20 mM). The reaction mixture was stirred at room temperature for two hours and then quenched with saturated aqueous
10 ammonium chloride. The organic layer was separated and the aqueous layer extracted with ethyl acetate(3 x 25 ml). The combined organic layers were washed with 10% aqueous sodium thiosulfate, brine, dried over sodium sulfate and concentrated *in vacuo*.


Chromatography over silica gel afforded the desired product, pure 3-ethyl *N*-nonyl succinimide.

15 ¹HNMR: δ 0.8 (3H, t), 0.9 (3H, t), 1.15-1.35 (12H, m), 1.45-1.65 (3H, m), 1.80-1.95 (1H, m), 2.35 (1H, dd), 2.6-2.95 (2H, m), 3.45 (2H, dd)

Example 30

3-(2-Aminoethylthio)-1-nonylpyrrolidine-2,5-dione

20



A mixture of *N*-nonyl maleimide (0.01 M) prepared as described in Example 12 above, mercapto ethylamine (0.01 M) and triethylamine (0.001 M) in acetonitrile (50 ml) was
25 stirred for 24 hours at room temperature. Acetonitrile was evaporated *in vacuo* and the residue obtained was triturated with ethyl acetate (25 ml). The resultant suspension was


filtered and the solid washed with ethyl acetate. The solid was then dried and characterised as the desired product, N-nonyl,3-mercapto ethylamino maleimide.

^1H NMR: δ 0.85 (3H, t), 1.15-1.35 (12H, m), 1.45-1.55 (2H, m), 2.55 (2H, dd), 3.1-3.3 (2H, m), 3.35-3.50 (4H, m), 4.1 (1H, dd), 7.5-7.9 (2H, broad)

5

Example 31

2-Ethyl-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)hexanamide



10


N-nonyl,3-mercapto ethylamino maleimide (0.5 mM) prepared as described in Example 30 above in 2ml of dichloromethane was treated with one equivalent of triethylamine and one equivalent of 2-ethylhexanoyl chloride. The reaction mixture was stirred for five hours. The dichloromethane was then evaporated to leave a residue to which a saturated sodium bicarbonate solution (2 ml) was added with stirring for 30 minutes, followed by ethyl acetate (2 ml) with stirring for a further 30 minutes. The ethyl acetate layer was then separated and concentrated to yield the desired product.

15

Example 32


Cyclopropyl-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide

20



The procedure of Example 31 was repeated using instead cyclopropanecarbonyl chloride.

25


Example 33**(4-Butylphenyl)-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide**

5

The procedure of Example 31 was repeated using instead 4-butylbenzoyl chloride.


Example 34**(4-Hexyloxyphenyl)-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide**

10



The procedure of Example 31 was repeated using instead 4-hexyloxybenzoyl chloride.


15

Example 35**(4-Methylphenyl)-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide**

20 The procedure of Example 31 was repeated using instead 4-methylbenzoyl chloride.

Example 36

(4-(tert-Butyl)phenyl-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide




5

The procedure of Example 31 was repeated using instead 4-*tert*-butylbenzoyl chloride.

Example 37

Cyclopentyl-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide, ethane

10




The procedure of Example 31 was repeated using instead cyclopentanecarbonyl chloride.


Example 38

Cyclohexyl-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide

15



20 The procedure of Example 31 was repeated using instead cyclohexanecarbonyl chloride.


Example 39**(4-Nitrophenyl)-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide**

5

The procedure of Example 31 was repeated using instead 4-nitrobenzoyl chloride.


Example 40**3-((2-(Dibutylamino)ethyl)amino)-1-nonylpyrrolidine-2,5-dione**

10



15

N-nonyl maleimide (0.02 mM) prepared as described in Example 12 above in 2 ml of acetonitrile was treated with one equivalent of triethylamine and one equivalent of N,N-dibutylethylenediamine. The reaction mixture was stirred for six hours and then the acetonitrile was evaporated. The residue obtained was treated with cold aqueous dilute hydrochloric acid solution and ethyl acetate, with stirring for one hour. The ethyl acetate layer was then separated and concentrated to give the desired product.


Example 41**3-((2-(Diethylamino)ethyl)amino)-1-nonylpyrrolidine-2,5-dione**

5

The procedure of Example 40 was repeated using instead 3-diethylamino-1-methylpropylamine.


Example 42**1-Nonyl-3-((4-piperidinylphenyl)amino)pyrrolidine-2,5-dione**

10



The procedure of Example 40 was repeated using instead 4-(piperidyl)aniline.

15

Example 43**3-(Hydroxyethylthio)-3-methyl-1-nonylpyrrolidine-2,5-dione**


20

A solution of N-nonyl citraconimide (0.5 mM) prepared as described in Example 5 above in dimethylformamide (10 ml) was treated with triethylamine (0.5 mM) and then

2-mercaptoethanol (0.5 mM) was added dropwise. The progress of the reaction was monitored by thin layer chromatography and when the starting material could no longer be detected the reaction mixture was concentrated *in vacuo*. The residue obtained was dissolved in ethyl acetate, washed with water and dried over sodium sulfate. Purification
5 by chromatography yielded the desired product.

Example 44


3-(2-Aminoethylthio)-3-methyl-1-nonylpyrrolidine-2,5-dione



The procedure of Example 43 was repeated using instead 2-mercaptoethylamine.

Example 45

3-Methyl-1-octyl-3-(octylamino)pyrrolidine-2,5-dione.



A solution of N-octyl citraconimide (0.223 g, 1 mM) prepared as described in Example 7
20 above in acetonitrile (2 ml) was treated with triethylamine (0.14 ml, 1 mM) and then octylamine (0.165 ml, 1 mM) was added dropwise. The progress of the reaction was monitored by thin layer chromatography and when the starting material could no longer be detected the reaction mixture was concentrated *in vacuo*. The residue obtained was dissolved in ethyl acetate, washed with water and dried over sodium sulfate. Purification
25 by chromatography yielded the desired product.

¹HNMR: δ 0.8 (6H, t), 1.10-1.28 (20H, m), 1.3 (3H, s), 1.32-1.58 (4H, m), 2.25-2.48 (2H, m), 2.50 & 2.80 (2H, ABq), 3.42 (2H, dd)

Example 46

5

Each of the compounds of Examples 1 to 45 was assessed for bactericidal activity against *M. tuberculosis* by measuring its minimum inhibitory concentration (MIC) in the "BACTEC" (trade mark) system developed by Becton-Dickinson Diagnostic Instrument Systems, Sparks, U.S.A., which is based on a radiometric principle whereby carbon dioxide
10 released by the catabolism of ¹⁴C-palmitate is spectrophotometrically detected and quantitated in arbitrary units of measurement referred to as growth index (GI) units.

Thus, "BACTEC" vials were inoculated with 0.1 ml of *M. tuberculosis* (final bacterial concentration, 1×10^5 colony forming units per ml) and 0.1 ml of test compound in a range
15 of concentrations. GI values were monitored until a value of ≥ 30 was achieved for the 1:100 dilution control.

For the purpose of this test, MIC is defined as the minimum concentration of test compound that effects a >95% inhibition of the culture in comparison to the undiluted
20 control, when the control reaches a GI value of 999.

Endpoint determination (>99% inhibition) is based on a conventional 1% resistance cut-off, wherein the organism is considered resistant to a particular concentration of test compound if growth of greater than 1% of the bacterial population is observed. Thus, a
25 comparison is made between growth of the organism in the presence of a pre-determined concentration of test compound and growth of the same organism diluted 1:100 in the absence of any test compound. The change in the GI values (Δ GI) is used to determine the endpoint susceptibility of the organism to the test compound. If the Δ GI of the 1:100 control is greater than the Δ GI in the presence of the test compound, then the concentration
30 of test compound used is considered to be bactericidal (>99% inhibition) for the organism.

The MIC of the compounds of Examples 1 to 46 were determined for the following strains of *M. tuberculosis*:

H37Rv,

H37Ra,

- 5 1 clinical isolate susceptible to isoniazid, rifampicin, ethambutol and streptomycin [E:22/95; Estonia],

1 clinical isolate resistant to isoniazid [H:997/94; Honduras], 1 clinical isolate resistant to isoniazid and ethambutol [E:5/94; Estonia],

1 clinical isolate resistant to isoniazid and rifampicin [H:44/95; Honduras],

- 10 1 clinical isolate resistant to isoniazid and streptomycin [S:150/96; Sweden],


1 clinical isolate resistant to isoniazid, rifampicin and streptomycin [AA:063; Ethiopia],

3 clinical isolates resistant to isoniazid, rifampicin, streptomycin and ethambutol [P:24/95; Estonia, S:39/95; Nepal, S:42/95; China, H:1005/94; Honduras],

- 15 and were found in all cases to be less than or equal to 20 µg/ml. Therefore, the compounds of Examples 1 to 46 demonstrate effective bactericidal activity against the above strains of *M. tuberculosis* which include single- and multiple-drug resistant strains.

C L A I M S

1. Use of a compound of general formula



wherein x is 0 or 1;

R¹ represents a hydrogen atom, or a C₁-C₂₀ alkyl or myrtanyl group, or a phenyl or benzyl group optionally substituted in the aromatic ring by one or more substituents selected from

- 10 amino, nitro, hydroxyl, carboxyl, halogen, trifluoromethyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxy carbonyl, piperidyl, piperazinyl and morpholinyl, or a group (CH₂)_yCONH-R⁵ where y is an integer from 1 to 6 and R⁵ represents a phenyl group optionally substituted by one or more substituents selected from amino, nitro, hydroxyl, carboxyl, halogen, trifluoromethyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxy carbonyl,
- 15 piperidyl, piperazinyl and morpholinyl; and

either

R² represents a hydrogen atom or a C₁-C₆ alkyl group, or R² together with R³ represents a carbon-carbon single bond provided that x is 0, or R² together with R⁴ represents a group =CH₂,

- 20 R³ represents a hydrogen atom or is linked to R² as defined above, and

R⁴ represents a hydrogen atom or a C₁-C₆ alkyl group; or a C₁-C₁₀ alkylamino group optionally substituted by a di(C₁-C₆ alkyl)amino substituent group; or an anilino group optionally substituted in the aromatic ring by one or more substituents selected from amino, nitro, hydroxyl, carboxyl, halogen, trifluoromethyl, C₁-C₆ alkyl, C₁-C₆ alkoxy,

- 25 C₁-C₆ alkoxy carbonyl, piperidyl, piperazinyl and morpholinyl; or a group-SCH₂CH₂OH,

-SCH₂CH₂NH₂, -SCH₂CH₂(NH₂)CO₂H or -SCH₂CH₂NHCO-R⁶ where R⁶ represents a C₁-C₁₀ alkyl or C₃-C₆ cycloalkyl group, or a phenyl group optionally substituted by one or more substituents selected from amino, nitro, hydroxyl, carboxyl, halogen, trifluoromethyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxycarbonyl, piperidyl, piperazinyl and morpholinyl; or R⁴ is linked to R² as defined above;

or

R², R³ and R⁴ together represent a phenyl group;

with the provisos that:

- (i) R¹, R², R³ and R⁴ do not each simultaneously represent a hydrogen atom,
 - (ii) when x is 0, R¹ represents a 4-fluorophenyl group and R⁴ represents a hydrogen atom, then R² and R³ do not together represent a carbon-carbon single bond, and
 - (iii) when x is 0, R¹ represents a 4-fluorophenyl group and R² and R³ both represent a hydrogen atom, then R⁴ does not represent an anilino, 4-chloroanilino, 2,6-dichloroanilino, 3,4-dichloroanilino, 2,5-dichloroanilino, 3-chloro-4-fluoroanilino or 4-fluoroanilino group;
- or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for use in the treatment of a mycobacterial disease.

2. Use according to claim 1, wherein R¹ represents a hydrogen atom, or a C₄-C₁₀ alkyl or myrtanyl group, or a phenyl group substituted by a piperidyl substituent group, or a group (CH₂)_yCONH-R⁵ where y is 1 or 2 and R⁵ represents a phenyl group substituted by a piperidyl substituent group.

3. Use according to claim 1 or claim 2, wherein R² represents a hydrogen atom or a methyl group, or R² together with R³ represents a carbon-carbon single bond provided that x is 0, or R² together with R⁴ represents a group =CH₂.

4. Use according to any one of claims 1 to 3, wherein R⁴ represents a hydrogen atom, a methyl or ethyl group, a C₂-C₁₀ alkylamino group optionally substituted by a di(C₂-C₄ alkyl)amino substituent group, an anilino group substituted by a piperidyl substituent group, -SCH₂CH₂OH, -SCH₂CH₂NH₂, -SCH₂CH₂(NH₂)CO₂H,

-SCH₂CH₂NHCO-R⁶ where R⁶ represents a C₇ alkyl, cyclopropyl, cyclopentyl or cyclohexyl group or a phenyl group substituted by a nitro, C₁-C₄ alkyl or C₃-C₆ alkoxy substituent group, or R⁴ is linked to R² as defined in claim 1.

5 5. Use according to claim 1 wherein the compound of formula (I) is selected from:

- 1-Decylpyrrolidine-2,5-dione,
- 1-Nonylpiperidine-2,6-dione,
- 2-((6,6-Dimethylbicyclo[3,1,1]hept-2-yl)methyl)isoindole-1,3-dione,
- 1-((6,6-Dimethylbicyclo[3,1,1]hept-3-yl)methyl)-3-methyl-3-pyrroline-2,5-dione,
- 10 3-Methyl-1-nonyl-3-pyrroline-2,5-dione,
- 3-Methylene-1-nonylpyrrolidine-2,5-dione,
- 3-Methyl-1-octyl-3-pyrroline-2,5-dione,
- 3-Methylene-1-octylpyrrolidine-2,5-dione,
- (4-(3-methyl-2,5-dioxo-3-pyrrolinyl)phenyl)piperidine,
- 15 1-Octyl-3-pyrroline-2,5-dione,
- 1-Decyl-3-pyrroline-2,5-dione,
- 1-Nonyl-3-pyrroline-2,5-dione,
- 1-Butyl-3-pyrroline-2,5-dione,
- 1-Hexyl-3-pyrroline-2,5-dione,
- 20 1-(4-Piperidylphenyl)-3-pyrroline-2,5-dione,
- 1-(Octyl-3-(octylamino)-pyrrolidine-2,5-dione,
- 1-Decyl-3-(decylamino)pyrrolidine-2,5-dione,
- 3-(Octylamino)-3-pyrrolidine-2,5-dione,
- 3-(Heptylamino)-1-nonyl pyrrolidine-2,5-dione,
- 25 1-Nonyl-3-(nonylamino) pyrrolidine-2,5-dione,
- 1-Nonyl-3-(octylamino) pyrrolidine-2,5-dione,
- 2-Amino-3-(3-methyl-1-nonyl-2,5-dioxo-pyrrolidin-3-ylthio)propanoic acid,
- 2-Amino-3-(3-methyl-1-octyl-2,5-dioxo-pyrrolidin-3-ylthio)propanoic acid,
- 2-Amino-3-(1-octyl-2,5-dioxo-pyrrolidin-3-ylthio)propanoic acid,
- 30 3-Methyl-1-octylpyrrolidine-2,5-dione,

- 3-Methyl-1-nonylpyrrolidine-2,5-dione,
2-(2,5-Dioxopyrrolidinyl)-N-(4-piperidylphenyl)ethanamide,
2-(2,5-Dioxopyrrolidinyl)-N-(4-piperidylphenyl)propanamide,
3-Ethyl-1-nonylpyrrolidine-2,5-dione,
5 3-(2-Aminoethylthio)-1-nonylpyrrolidine-2,5-dione,
2-Ethyl-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)hexanamide,
Cyclopropyl-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide,
(4-Butylphenyl)-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide,
(4-Hexyloxyphenyl)-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide,
10 (4-Methylphenyl)-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide,
(4-(tert-Butyl)phenyl)-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide,
Cyclopentyl-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide, ethane,
Cyclohexyl-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide,
(4-Nitrophenyl)-N-(2-(1-nonyl-2,5-dioxopyrrolidin-3-ylthio)ethyl)formamide,
15 3-((2-(Dibutylamino)ethyl)amino)-1-nonylpyrrolidine-2,5-dione,
3-((2-(Diethylamino)ethyl)amino)-1-nonylpyrrolidine-2,5-dione,
1-Nonyl-3-((4-piperidylphenyl)amino)pyrrolidine-2,5-dione,
3-(Hydroxyethylthio)-3-methyl-1-nonylpyrrolidine-2,5-dione,
3-(2-Aminoethylthio)-3-methyl-1-nonylpyrrolidine-2,5-dione, and
20 3-Methyl-1-octyl-3-(octylamino)pyrrolidine-2,5-dione.
6. Use according to any one of the preceding claims wherein the mycobacterial disease is tuberculosis.
- 25 7. A method of treating a patient suffering from, or at risk of, a mycobacterial disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as defined in claim 1.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/00732

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 31/40, A61K 31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Indian Drugs, Volume 29, No 7, 1982, A. A. Korhalkar et al, "Synthesis of 2-hetero/aryl-N-(p-fluorobenzene) succinimide derivatives as antitubercular agents" page 306 - page 307 -- -----	1-6



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

20 July 1999

Date of mailing of the international search report

16-09-1999

Name and mailing address of the ISA

Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Göran Karlsson/Els
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE99/00732

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 7
because they relate to subject matter not required to be searched by this Authority, namely:
**A method for treatment of the human or animal body by therapy,
see rule 39.1.**
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such
an extent that no meaningful international search can be carried out, specifically:

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.